Secukinumab, an anti-IL17 antibody, has been employed in cases of refractory LN [254] and is currently being assessed in phase III trials (ClinicalTrials.gov Identifier: NCT04181762) (Figure 5). Here, IL17A is linked to lobular neoplasia.